Skip to search formSkip to main contentSkip to account menu

BMS 582664

Known as: BMS-582664, BMS582664 
A vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. BMS-582664 strongly binds to and inhibits… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

brivanibbrivanib alaninate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A phases II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
e16599 Background: Brivanib (BMS582664) is an oral, multi-targeted tyrosine kinase inhibitor against vascular endothelial growth… 
2012
2012
Acid-catalyzed hydrolysis of BMS-582664: degradation product identification and mechanism elucidation.
BMS-582664 is an investigational drug intended for cancer treatment through oral administration. The preformulation studies… 
2011
2011
Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.
10000 Background: Pts with sarcomas, a family of >70 types of cancer, have limited options once cytotoxic agents fail. Brivanib… 
Review
2011
Review
2011
Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).
3079 Background: Brivanib (B) is an oral once daily selective dual inhibitor of FGF and VEGF signaling currently in phase III… 
2008
2008
A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced…
4111 Background: Brivanib alaninate (B) is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR… 
2007
2007
A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK…
3559 Background: Brivanib is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling. Part A… 
2007
2007
A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal…
14018 Background: Brivanib is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling. Prior… 
2007
2007
BMS-582664, a dual inhibitor of VEGF and FGF signaling pathways, induces growth suppression and apoptosis in mouse models of hepatocellular carcinoma
A31 Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, with no effective treatment for most… 
2006
2006
Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors.
3051 Background: This is the first multiple-dose study with BMS-582664, an oral VEGFR/FGFR tyrosine kinase inhibitor (IC50 34, 10… 
2005
2005
Preclinical studies of BMS-582664, an alanine prodrug of BMS-540215, a potent, dual inhibitor of VEGFR-2 and FGFR-1 kinases
Proc Amer Assoc Cancer Res, Volume 46, 2005 3033 The growth, survival and dissemination of tumors is critically dependent on… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)